Keywords: Eisai, Perampanel, Phase III, Epilepsy

Eisai reports positive Ph III results for perampanel in partial epilepsy

Article | 25 August 2010

Print This

Japan’s fourth largest drugmaker Eisai (TYO: 4523) has announced encouraging results of a Phase III study for the investigational compound ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in